Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization
about
Making the most of clinical data: reviewing the role of pharmacokinetic-pharmacodynamic models of anti-malarial drugsArtemisinin Action and Resistance in Plasmodium falciparumNew developments in anti-malarial target candidate and product profilesTargeting the cell stress response of Plasmodium falciparum to overcome artemisinin resistanceLong-Term Prophylaxis and Pharmacokinetic Evaluation of Intramuscular Nano- and Microparticle Decoquinate in Mice Infected with P. berghei Sporozoites.Emergence of resistance to atovaquone-proguanil in malaria parasites: insights from computational modeling and clinical case reportsPopulation Pharmacokinetics and Antimalarial Pharmacodynamics of Piperaquine in Patients With Plasmodium vivax Malaria in ThailandEfficacy of intranasal administration of artesunate in experimental cerebral malariaArtemisinin combination therapy: a good antimalarial, but is the dose right?Pharmacokinetic-pharmacodynamic analysis of spiroindolone analogs and KAE609 in a murine malaria model.Triaminopyrimidine is a fast-killing and long-acting antimalarial clinical candidate.Rethinking Dosing Regimen Selection of Piperaquine for Malaria Chemoprevention: A Simulation Study.Using Chemical Reaction Kinetics to Predict Optimal Antibiotic Treatment Strategies.Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers.A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study.Quantifying the pharmacology of antimalarial drug combination therapy.Evaluation of pharmacokinetics of single-dose chloroquine in malnourished children with malaria- a comparative study with normally nourished childrenEstimation of the In Vivo MIC of Cipargamin in Uncomplicated Plasmodium falciparum Malaria.Malaria parasite clearance.Pharmacological considerations in the design of anti-malarial drug combination therapies - is matching half-lives enough?Use of quantitative pharmacology tools to improve malaria treatments.Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic.The application of physiologically-based pharmacokinetic modelling to assess the impact of antiretroviral-mediated drug-drug interactions on piperaquine antimalarial therapy during pregnancy.Comparison of the Exposure Time Dependence of the Activities of Synthetic Ozonide Antimalarials and Dihydroartemisinin against K13 Wild-Type and Mutant Plasmodium falciparum Strains.Pharmacokinetic studies of antimalarials: recent developments.Modelling mosquito infection at natural parasite densities identifies drugs targeting EF2, PI4K or ATP4 as key candidates for interrupting malaria transmission.A Dynamic Stress Model Explains the Delayed Drug Effect in Artemisinin Treatment of Plasmodium falciparum.Inhibiting the Plasmodium eIF2α Kinase PK4 Prevents Artemisinin-Induced Latency.Tools for surveillance of anti-malarial drug resistance: an assessment of the current landscape.Characterizing Blood-Stage Antimalarial Drug MIC Values In Vivo Using Reinfection Patterns.Superior Pyronaridine Single-Dose Pharmacodynamics Compared to Artesunate, Chloroquine, and Amodiaquine in a Murine Malaria Luciferase ModelImplications of population-level immunity for the emergence of artemisinin-resistant malaria: a mathematical model
P2860
Q27025529-9962550F-5BA4-4188-B708-81C9DC170574Q28276294-49BE6E0E-A43A-4DA8-8149-E52E4ACA63E3Q28468598-6A44A02F-6664-42C8-BAD2-76F2B5A61740Q28546636-0AC3AF5A-B14D-49DE-A19D-9E6B31CD6355Q33607991-C6798FA0-855C-4FFC-8634-96B391E347BAQ34058304-F947D377-69F2-43A6-ADC8-3C532378B21CQ34116219-78F36E2F-45AC-42F2-863D-F07E24A1AD3EQ35060339-C6240CD9-BBF0-4A29-AAF0-06CAFB6C62B2Q35069127-1B0A5E14-E241-4A65-9F4F-5E0F9C50C431Q35105913-58D6E3C7-3A37-45D2-9C56-C5F35FFB27D3Q35311620-795A157F-4A42-4FB0-9FD1-2E048EAD0E74Q36018444-C7AE66EF-77E6-4D43-A3B4-94112A028C3DQ36242447-C2365A5F-D941-4FE2-AD0E-016614589E04Q37193141-C0B56820-EED7-4060-8D48-94FBBB4B0840Q37254756-511DC5F7-A43E-45F2-8EA7-B8B269242EC2Q37283299-272E8DBD-4BFB-4E2D-9DBF-BE41B625BC3CQ37311950-413396FA-2BD3-4CEA-ABDF-E0614A03EF05Q37613014-CCFB567D-94BF-4B0F-8D03-9ACEC50ED4CAQ37663369-8F6C851B-306C-47A8-B33A-41B0B32A2958Q37685088-BF26CEDA-9493-4D8A-8F32-4D0C58F9C241Q38664529-F72D7DE2-19E5-4036-80B5-F63981A2B357Q40106428-12FE5B70-E4A3-440D-85C1-3711BE626F2DQ40133890-1D47B687-9956-4FC3-B8C9-BAF15488A7FCQ40762488-FF493CBB-B786-4041-BDED-3CA655E86E9BQ43848645-FE78C2FA-7B0A-4CCC-8CE1-DB8BC171607FQ47096821-F5987372-D830-436B-9FAE-D08140DA13F5Q47100908-D097409A-653A-4444-BC6D-1D922036A539Q48019234-081AF6AB-0DCD-4CEF-8A9D-3692FF0C2732Q50052786-8F022372-0A68-4A63-8ECA-E75570B8076EQ55513666-E6AE747F-BAB5-423C-A37E-120F94816FDDQ56339840-62B95B06-92B9-4AA0-8B92-5DA3D50ED032Q56348478-EB3D9C4F-615B-43F3-89C5-F560EE96870F
P2860
Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization
@ast
Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization
@en
Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization
@nl
type
label
Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization
@ast
Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization
@en
Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization
@nl
prefLabel
Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization
@ast
Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization
@en
Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization
@nl
P2860
P921
P3181
P356
P1476
Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization
@en
P2093
N. J. White
P2860
P304
P3181
P356
10.1128/AAC.00287-13
P407
P5008
P577
2013-12-01T00:00:00Z